Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models by Moore, Lindsay S. et al.
  
 University of Groningen
Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck
cancer models
Moore, Lindsay S.; de Boer, Esther; Warram, Jason M.; Tucker, Matthew D.; Carroll, William






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Moore, L. S., de Boer, E., Warram, J. M., Tucker, M. D., Carroll, W. R., Korb, M. L., ... Rosenthal, E. L.
(2016). Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck
cancer models. Cancer medicine, 5(7), 1526-1534. https://doi.org/10.1002/cam4.752
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Obtaining complete removal of tumor tissue while mini-
mizing damage to surrounding healthy tissue with improved 
disease- free and overall survival is the ultimate goal of 
surgical treatment of squamous cell carcinoma of the head 
and neck (SCCHN) [1, 2]. Despite efforts to utilize more 
advanced surgical and medical technologies, the 5- year 
survival rate has had modest improvement over the past 
three decades, remaining in the range of 50–55% [3, 4]. 
Locoregional recurrence is the most common cause for 
treatment failure, and the prevalence of positive tumor 
margins is approximately 30% of surgical resections in 
current clinical practice [4, 5]. Adjuvant treatments 
intended to eliminate residual disease after incomplete 
resections, including radiation and chemotherapy, can 
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Abstract
Antibody- based photodynamic therapy, or photoimmunotherapy (PIT), is a 
novel, targeted cancer therapy, which can serve as both a diagnostic and a 
therapeutic agent. The primary objective of this study was to evaluate the  capacity 
of panitumumab- IRDye700DX (Pan- IR700) to eliminate microscopic tumor 
remnants in the postsurgical setting, which was accomplished using novel in 
vitro and in vivo models of residual disease after incomplete resection. 
 Additionally, PIT was evaluated in fresh human- derived cancer tissue. To 
 determine a threshold for cellular regrowth after PIT, an in vitro assay was 
performed using a range of cells representing microscopic disease quantities. 
Long- term growth inhibition was induced after treatment of 5 × 103 and 1 × 104 
cells at 6 J. A novel in vivo mouse model of subtotal tumor resection was used 
to assess the effectiveness of Pan- IR700 mediated PIT to eliminate residual 
disease and inhibit recurrence in the post- surgical wound bed. Mice receiving 
surgical treatment plus adjuvant PIT showed a threefold and fourfold reduction 
in tumor regrowth at 30 days post PIT in the 50% and 90% subtotal resection 
groups, respectively (as measured by bioluminescence imaging), demonstrating 
a significant (P < 0.001) reduction in tumor regrowth. To determine the trans-
latability of epidermal growth factor receptor (EGFR)- targeted PIT, SCCHN 
human tissues (n = 12) were treated with Pan- IR700. A significant reduction 
(P < 0.001) in ATP levels was observed after treatment with Pan- IR700 and 
100 J cm−2 (48% ± 5%) and 150 J cm−2 (49% ± 7%) when compared to 
baseline. Targeting EGFR with Pan- IR700 has robust potential to provide a 
tumor- specific mechanism for eliminating residual disease in the surgical setting, 
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themselves fail to control disease recurrence and are asso-
ciated with severe side effects. As such, there is an acute 
need for targeted treatment modalities that can facilitate 
total disease eradication to improve patient outcomes while 
limiting collateral damage of precious healthy tissues.
Antibody- based photodynamic therapy, or photoim-
munotherapy (PIT), is a novel, cancer- targeted treatment 
modality that has demonstrated promise to improve the 
balance between efficacy and toxicity in the management 
of solid malignancies [6–11]. Traditional photodynamic 
therapy, while effective in killing cancer cells, employs 
nontargeted photosensitizers that induce light- dependent 
cytotoxicity to noncancerous cells, resulting in severe side 
effects and limiting clinical translatability [7]. Alternatively, 
PIT utilizes the specificity of antibody binding to deliver 
therapeutic phototoxicity to malignant cells aberrantly 
overexpressing target receptors while sparing adjacent 
normal tissues [7–10].
However, the strategy of using antibodies to target 
delivery of an optically active molecule to cancer cells is 
not unique to PIT. The field of fluorescence- guided surgery 
has demonstrated the ability of a number of various 
fluorophore- antibody combinations to successfully provide 
cancer- specific fluorescent contrast to help delineate cancer 
margins during surgical resection [12]. Given the obvious 
overlap between these applications, experts in both fields 
have recognized the potential to combine the technologies 
to explore a dual diagnostic and therapeutic paradigm, 
and have already demonstrated early success in this pro-
posed model [6–9]. In this approach, antibodies are con-
jugated to a fluorescent photosensitizer, such as 
IRDye700DX, and act as targeting vectors that specifically 
deliver the photosensitizer to the tumor. Upon antibody 
binding to cancer cells, a relatively brief exposure from 
an external light source can be used for fluorescence 
imaging to localize the tumor for diagnostic purposes 
(Fig. 1A and B), while high- energy excitation from an 
external light source produces cytotoxic light emissions 
from the photosensitizer that induce localized cell death 
(Fig. 1C) [7, 8]. In the intraoperative or endoscopic set-
ting, this technique could be applied to the post- resection 
wound bed as a surgical adjuvant to specifically treat 
unrecognized positive margins or microscopic residual 
disease.
While research has been conducted to assess the ability 
of fluorescent photosensitizers to provide tumor- specific 
contrast (as in Fig. 1A) and to quantify tumor suppres-
sion in in vitro and whole tumor in vivo models [6–11], 
there are no studies specifically exploring the feasibility 
or value of a fluorescent photosensitizer in the proposed 
role of treating residual disease in a post- surgical wound 
bed (Fig. 1B). Therefore, the objective of this study was 
to evaluate the performance of the fluorescent photosen-
sitizer IRDye700DX conjugated to the anti- epidermal 
growth factor receptor (EGFR) monoclonal antibody 
 panitumumab (panitumumab- IRDye700DX; Pan- IR700) 
as a PIT agent to eliminate microscopic residual disease 
in a wound bed following incomplete surgical resection 
in a model of SCCHN. This was accomplished using an in 
vitro model assessing a range of quantities representing 
microscopic disease to establish the cellular threshold of 
tumor suppression and a novel in vivo model of residual 
disease after incomplete resection.
Obviously, given the ability of Pan- IR700 to induce 
tumor- specific cell death without toxic side effects and 
its potential as a dual therapeutic and diagnostic agent, 
the feasibility and value of clinical translation of this 
technology into humans is quite promising. However, data 
Figure 1. PIT- guided surgery. The mAb- photosensitizer construct is administered systemically. (A–B) The tumor- targeted mAb will allow for real- time 
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to describe the therapeutic potential of PIT using 
IRDye700DX conjugated to monoclonal antibodies (mAb) 
is currently limited to a single laboratory [7, 9–11], and 
no studies have been conducted to test this agent in 
human tissue. Therefore, a second objective of this study 
was to explore the phototoxic efficacy of Pan- IR700 in 
an ex vivo model using fresh, patient- derived SCCHN 
tissue samples.
Material and Methods
Cell lines and animal models
For this study, the luciferase- expressing SCCHN 1 (SCC- 
1- Luc) was used. The cell line was obtained from Dr. 
Thomas Carey (University of Michigan, Ann Arbor, MI) 
and maintained in Dulbecco Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 1% L- glutamine. The cell line was cultured at 37°C 
in a humid atmosphere with 5% CO2. Cells were passaged 
at 80–90% confluence and harvested with 0.05% trypsin. 
A hemocytometer with trypan dye exclusion was used to 
quantify cell numbers.
For the animal models, athymic female nude mice, aged 
5–6 weeks (Frederick Cancer Research, Frederick, MD) 
were obtained and housed in accordance with guidelines 
and regulations of the Institutional Animal Care and Use 
Committee (IACUC). For subcutaneous inoculation, 
2 × 106 cells/100 μL Dulbecco’s modified Eagle medium 
(without FBS) were subcutaneously implanted in the left 
flank. Tumor growth was monitored by bioluminescence 
imaging (BLI, photons/sec/cm2/sr; IVIS- 100, Caliper Life 
Sciences, Waltham, MA) and visual inspection two times 
per week. Eight weeks post implantation, mice were sorted 
into four groups (n = 3) based on tumor luciferase expres-
sion as determined by BLI to achieve equal distribution 
of tumor size and growth rate. All animal experiments 
were performed according to approved IACUC 
protocols.
Panitumumab- IRDye700DX conjugation
Conjugation of the fully humanized anti- EGFR mAb pani-
tumumab to the photosensitizer IRDye700DX (absorption 
max: 689 nm, emission max: 700 nm) was performed as 
previously described [8]. Briefly, panitumumab (Pan; 
Vectibix, Amgen, Thousand Oaks, CA; 177 kDa) was 
diluted to 5 mg mL[1] in PBS. IRDye700DX NHS ester 
(IR700; LI- COR Biosciences, Lincoln, NE; 2.0 kDa), which 
allows for reproducible, single- step covalent protein con-
jugations [7], was conjugated to panitumumab for 2 h 
at room temperature in the dark, at a molar ratio of 2:1. 
After purification using a desalting spin column (Pierce 
Biotechnology, Rockford, IL) to remove unconjugated dye, 
the final protein concentration and number of dye mol-
ecules per protein were measured by UV- Vis spectroscopy 
(Nanodrop 200- c, ThermoScientific, Wilmington, DE).
In vitro microscopic disease model 
proliferation assay
SCC- 1- Luc cells were seeded into a 24- well, black- welled 
plates (Wallac) at a concentration of 5 × 103, 1 × 104, 
2.5 × 104, and 5 × 104 cells per well. One day after 
seeding, cells were treated accordingly: (1) no treatment; 
(2) PIT at 6 J cm−2; (3) Pan- IR700 and PIT at 6 J cm−2. 
Pan- IR700 dose was 10 μg mL−1. Cell viability was deter-
mined by BLI at 8 h, 1, 2, 4, and 5 days after PIT 
mediated or not mediated Pan- IR700 treatment. BLI signal 
was measured daily, and the fold increase in BLI signal 
over time from the baseline value was calculated.
In vivo xenograft model of residual disease 
after incomplete resection
The mice were sorted into four groups (n = 3): subtotal 
surgical resection of 90% or 50% + 300 μg 
Pan- IR700 + 100 J; subtotal surgical resection of 90% or 
50% + 300 μg Pan- IR700 alone as previously described 
[13]. Pan- IR700 was dosed intravenously via tail vein. In 
mice in the 90% subtotal resection group, 10% of the 
tumor was left in the wound cavity; and in mice in the 
50% subtotal resection group, 50% of the tumor was left 
in the wound cavity, as determined by weight. All mice 
underwent identical surgical procedures. Briefly, 1 day 
post Pan- IR700 injection, mice received 2.5 mg D- luciferin 
intraperitoneally (IP) 10 min prior to tumor resection. 
After anesthetizing the mice, the tumors were removed 
and appropriate amounts of tumor (i.e., 90% or 50%) 
was removed from the resected tumor, and remaining 
amounts (resp. 10% and 50%) placed back in the wound 
bed. BLI was then performed on the wound bed to con-
firm the presence of luciferase- positive cancer. Fluorescence 
imaging of the wound bed was also performed using a 
closed- field imaging system (Pearl, LI- COR Biosciences, 
Lincoln, NE) specifically designed for the IR700 fluorescent 
spectrum. Following tumor imaging, dependent on the 
group, the wound bed was exposed to 100 J or 0 J. 
Subsequently, the wound bed was closed using 6- O fast- 
absorbing plain gut suture using a PC- 1 conventional 
cutting 3/8 circle needle (1916, Ethicon, San Angelo, TX). 
The mice were subcutaneously injected with a 100 μg 
cocktail of 1 mg mL−1 carprofen and 20 μg mL−1 buprenor-
phine to relieve residual pain from surgery. The mice 
were allowed to heal for 4 days before follow- up BLI 
began. BLI signal was determined at each imaging time 
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point, and fold increase in BLI signal at each time point 
from the baseline measurement immediately following 
tumor fragment reimplantation was calculated. All appli-
cable institutional guidelines for the care and use of animals 
were followed.
Ex vivo model of patient- derived tissue 
samples
Tumor specimens (n = 12) were obtained from histologi-
cally confirmed SCCHN patients at the time of resection 
and placed in complete culture media (DMEM supple-
mented with 10% FBS, 1% penicillin- streptomycin, and 
1% gentamycin). Within 1 h post specimen retrieval, 
multiple tissue slices (3–6 replicate slices per treatment 
group) measuring approximately 4 mm in diameter and 
1–2 mm in thickness were obtained via biopsy punches 
and sharp dissection. Tumor slices were weighed and 
randomly placed into individual wells of 24- well plates 
in 0.5 mL of complete media supplemented with unlabeled 
panitumumab (0.02 mg mL−1), Pan- IR700 (0.02 mg mL−1), 
or no antibody and incubated at 37°C in 5% CO2 for 
24 h. Tumor slices were then washed three times in PBS. 
Complete media was added to the specimens and LED 
illumination was applied at 50 J cm−2, 100 J cm−2 , or 
150 J cm−2 to individual antibody- treated groups. Twenty- 
four hours post PIT, an ATP viability assay was performed 
on sonicated tissue slices as previously described [14]. 
Therapeutic effect is expressed as percent ATP level com-
pared to the control. All patients were given informed 
consent and the Institutional Review Board approval was 
obtained for procurement and ex vivo treatment of tissue 
specimens.
Flow cytometry
Patient- derived tumor slices were incubated with Pan- IR700 
in a 1:10 serial dilution (20 μg mL−1 – 0.02 μg mL−1) 
in triplicate. After washing, wells were fluorescently imaged 
using a fluorescence scanner (Odyssey, LI- COR). After 
imaging the tumor slices in the fluorescent scanner, speci-
mens were homogenized to generate single- cell suspensions 
that were subsequently analyzed for fluorescent count in 
the 700 channel using a flow cytometer (Accuri Cytometers 
inc, Ann Arbor, MI).
Histology
Patient- derived tumor slices were incubated with Pan- IR700 
at a concentration of 20 μg mL−1 in triplicate. After wash-
ing, specimens were formalin- fixed, paraffin- embedded, 
cut and mounted on glass slides. IR700 fluorescence 
intensity was measured on specimen- mounted slides using 
a fluorescence scanner (Odyssey, LI- COR). Immunohisto-
chemistry was performed to evaluate EGFR density (anti- 
human EGFR Ab- 10, Thermoscientific, Waltham, MA). 
Subsequently, a board- certified pathologist confirmed the 
presence of tumor within EGFR- stained sections (MBG).
Statistics
Data are expressed as means ± standard error of the 
mean (s.e.m.). Independent and paired samples t- tests 
were used to compare treatment effects with that of con-
trols. For all statistical analyses, SPSS (version 21.0) was 
used. P- value <0.05 was considered to indicate a statisti-
cally significant difference.
Results
PIT induces growth inhibition of 10,000 cells 
in an in vitro mode of microscopic residual 
disease
To establish a threshold for cellular regrowth after PIT, 
an in vitro assay was performed using luciferase- positive 
SCC- 1- Luc cells of varying amounts to represent micro-
scopic disease quantities. Cells were treated with 10 μg 
mL−1 Pan- IR700 followed by 6 J of LED illumination. 
Significant cytotoxicity was achieved with treatment of 
6 J and Pan- IR700, but no cytotoxicity was observed with 
6 J alone in any cell concentration (Fig. 2A). Longer 
term growth inhibition was seen in lower density cell 
platings treated with Pan- IR700 mediated PIT (Fig. 2B; 
P < 0.05 at 4 days and 5 days post PIT). At day 5, a 
47- fold and 10- fold increase in luminescent counts was 
observed for the 2.5 × 104 and 5 × 104 cells compared 
to the 5x103 and 1x104 cells, respectively. However, in 
the groups with 5 × 103 and 1 × 104 cells, long- term 
growth inhibition was observed in response to Pan- IR700 
mediated PIT.
PIT with Pan- IR700 suppresses disease 
recurrence in an animal model of 
incomplete resection
To assess the efficacy of PIT using Pan- IR700 as a post-
surgical treatment option to eradicate residual disease, a 
novel in vivo model of incomplete resection was developed. 
Mice receiving surgical treatment plus adjuvant PIT on 
the surgical wound bed showed a significant (P < 0.001) 
reduction in growth over the 4- week observation period 
compared to mice that did not receive adjuvant PIT 
(Fig. 3). No significant change in tumor size was observed 
over time in mice receiving surgical treatment plus adju-
vant PIT (P < 0.05). However, in mice that received 
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surgical therapy only, a significant increase in tumor size 
and BLI signal was observed in both subtotal resection 
groups from day 15 on (P < 0.05). As detailed in Figure 3, 
mice that underwent postoperative PIT on the wound 
bed showed a threefold and fourfold reduction in tumor 
regrowth at 30 days post PIT in the 50% and 90% sub-
total resection groups respectively, as measured by BLI.
PIT with Pan- IR700 decreases cell viability in 
patient- derived SCCHN tissue
To determine the translatability of EGFR- targeted PIT in 
humans, we obtained SCCHN human tissue samples 
(n = 12) and treated ex vivo with Pan- IR700 (Fig. 4). 
Values are reported as mean percentage ATP levels of 
untreated controls (0 J cm−2, 0 μg mL−1). Tissue speci-
mens exposed to light alone (50 J cm−2, 100 J cm−2 or 
150 J cm−2) did not demonstrate a significant difference 
from baseline (P > 0.05). Moreover, tissue treated with 
Pan- IR700 alone did not demonstrate a significant dif-
ference from baseline in tissue viability (P > 0.05). A 
significant decrease in cell viability was not observed in 
tissue treated with Pan- IR700 and 50 J cm−2. However, 
a significant reduction (P < 0.001) in ATP levels was 
observed after treatment with Pan- IR700 and 100 J cm−2 
(48% ± 5%) and 150 J cm−2 (49% ± 7%) when compared 
to baseline. There was no significant difference in cell 
viability levels between these two groups.
Figure 2. Pan- IR700- mediated photoimmunotherapy in vitro. (A) A significant reduction in viability was obtained with the treatment of 10 μg/mL 
Pan- IR700- mediated PIT at 6 J compared to control cells exposed to 0 J and 6 J only (P < 0.001). (B) Proliferation assay after Pan- IR700 (10 μg/mL)- 
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Figure 3. Bioluminescence imaging of tumor viability after surgical resection. Mice treated with PIT exhibit significantly less tumor regrowth in each 
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Pan- IR700 localizes to EGFR+ tumor regions 
in human- derived SCCHN tumor specimens
Human SCCHN cells and tissues were treated with 
Pan- IR700 and fluorescence histology was compared to 
histopathology to assess the specificity of Pan- IR700 bind-
ing. Pan- IR700 was shown to stain the tissue in a dose- 
dependent manner and generated fluorescence when 
imaged in wells using a fluorescent flatbed scanner (Fig. 
5A and B; Odyssey, LI- COR). Fluorescence localization 
was explored in whole tissue specimens and in single- cell 
suspensions. When tumor specimens were homogenized 
and cellular fluorescence was quantified using flow cytom-
etry, a dose- dependent expression of fluorescence was 
observed (Fig. 5B). When specimens were analyzed his-
tologically, tumor- containing areas, identified using H&E 
staining (Fig 5C; annotated by board- certified pathologist 
[MBG]), expressed higher levels of EGFR compared to 
normal tissue (Fig 5D). The areas of highest fluorescence 
were shown to co- localize with areas of high EGFR expres-
sion and cancer- containing tissue (Fig. 5E; Odyssey, 
LI- COR).
Discussion
Surgical resection and adjuvant radiotherapy or chemo-
radiation is considered the gold standard for treatment 
of SCCHN [1, 2]. However, recurrence rates remain high 
(50–55%), and predominantly occur locoregionally due 
to microscopic residual cancer cells left in the post- resection 
wound bed [3, 4]. The complex geometry and topography 
of head and neck anatomy, as well as the abundance of 
vital structures, make complete resections with disease- free 
margins particularly challenging in this region. In addition 
to the severe side effects associated with adjuvant 
treatments, the devascularized and hypoxic nature of the 
post- surgical wound bed compromises the delivery of any 
adjuvant systemic drugs and radiotherapy, respectively. 
Photoimmunotherapy is a promising treatment modality 
that could provide cancer- targeted therapy to eliminate 
residual disease without the damage to normal tissues 
and side effects that current adjuvant treatments and even 
traditional photodynamic therapy entail [7–11].
Given the development of molecular dyes that can act 
as both fluorophores and photosensitizers, such as the 
IRDye700DX explored in this study, PIT has long been 
envisioned to function in the clinical setting as a valuable 
combination of the two technologies [7–11]. Antibody- 
based targeted delivery of photosensitizing fluorophores 
to cancer offers the potential for real- time, intraoperative 
localization to guide resection with fluorescence and local-
ized, intra- and post- operative phototoxic treatment of 
any residual disease with a single agent. The application 
of this dual technique in the wound bed is particularly 
pertinent, as the relatively superficial location of residual 
cancer in the wound bed optimizes both technologies by 
eliminating artifacts like attenuation and scattering that 
can limit efficacy in deeper tissues [15]. Furthermore, 
administration of the agent prior to wound bed devas-
cularization, the long half- life of antibody- based probes, 
the mechanism of action, and the superficial and localized 
nature of PIT imply that this treatment would not be 
limited by the poorly vascularized and hypoxic environ-
ment of the postsurgical wound bed.
Current literature concerning PIT includes a number 
of studies exploring the fluorescence potential of photo-
sensitizing fluorophores, like Pan- IR700, as well as its 
phototoxic efficacy to treat whole tumors [7–11]. However, 
there is a paucity of data actually exploring the efficacy 
of PIT in its proposed role as a postsurgical adjuvant 
Figure 4. Pan- IR700- mediated PIT in SCCHN patient specimens. (A) Viability for head and neck cancer tissue slices (n = 12) per treatment group. A 
significant reduction in ATP levels was obtained in tissues treated with 20 μg/mL Pan- IR700 and 100 J and 150 J (P < 0.001). (B) Representative data 
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treatment. Thus, the primary objective of this study was 
to elucidate the efficacy of PIT using Pan- IR700 to eradi-
cate microscopic residual disease in the wound bed after 
incomplete resection, which was assessed using in vitro 
and in vivo models of microscopic and residual disease, 
respectively. We also explored, for the first time, the per-
formance of PIT in fresh human SCCHN tissue.
First, PIT was tested on a range of cells representing 
increasing microscopic quantities to establish a numerical 
threshold of effective phototoxic therapy. Long- term growth 
inhibition after Pan- IR700 mediated PIT treatment was 
observed for 5 × 103 and 1 × 104 cells in this in vitro 
model. However, regrowth eventually occurred in the 
2.5 × 104 and 5 × 104 groups, suggesting that, for a 
single PIT treatment (6 J cm−2, 10 μg mL−1 Pan- IR700) 
the threshold of effective growth suppression lies some-
where between 10,000 and 25,000 cells. This finding sug-
gests that PIT is more effective with fewer cells, further 
supporting its use to treat residual microscopic disease 
instead of large, unresected tumor masses.
Assuming that there are approximately 1 × 108 cells 
in 1 cm3 (approximately 1.0 g) of tumor tissue [16], 
10,000 cells would represent less than 1 mm3. Given that 
1 cm3 is generally presumed to be the amount of tumor 
discernible by the human eye, there is likely a range of 
subclinical disease that cannot be effectively treated with 
a single PIT treatment at this time. However, repeated 
PIT treatments have demonstrated significantly improved 
cell killing compared to single- treatment regimens [11]. 
If this in vitro study were presumed to be translatable 
in a biological system, one could conclude that multiple 
treatments would be recommended in the case of positive 
margins or suspected incomplete resections; however, given 
the noninvasive nature of light therapy and the data sug-
gesting minimal side effects with PIT, this would arguably 
be a welcome alternative to chemo- or radiotherapy, 
although testing this model with repeated treatments would 
be needed to draw definitive conclusions. It is important 
to consider, however, that a single, intraoperative light 
treatment easily applied to the exposed wound bed of 
any patient with apparently “clean” margins not requiring 
adjuvant therapy would theoretically be substantial enough 
to effectively treat the ultra- microscopic nests (well under 
10,000 cells) that may not be included in frozen sections 
taken of a margin. Furthermore, some fluorescence imag-
ing systems are reportedly able to detect as little as 0.1 mg 
Figure 5. Histology. (A) Fluorescence was shown to stain the tissues in a dose- dependent manner when imaged in wells with the fluorescent Odyssey 
scanner. (B) After homogenizing the tissue, dose- dependent cellular fluorescence was shown using flow cytometry. Representative H&E, EGFR, and 
fluorescence image. (C–E) Tumor- containing areas (annotated by black line) contained relatively higher levels of EGFR expression and highest 
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of tumor (unpublished data), suggesting that using fluo-
rescent photosensitizers in their dual diagnostic and thera-
peutic role could narrow the gap between tumor able to 
be visually resected and residual microscopic disease ame-
nable to a single PIT treatment.
More importantly, long- term growth inhibition of 
residual disease was observed in a novel mouse model 
of incomplete surgical resection, in which either 50% or 
10% of the tumor was left in the wound bed. In order 
to ensure accuracy and establish standardization in this 
model, the entire tumor was resected and weighed to 
provide a quantitative method of determining the precise 
amount of tumor to be returned to the wound bed. In 
this study, a single NIR light irradiation was effective in 
inducing long- term growth inhibition. Importantly, greater 
growth suppression was achieved in the 90% resection 
group, once again suggesting increasing efficacy of this 
treatment modality with decreasing amounts of residual 
tumor. Ultimately, however, local recurrences were seen 
in treated mice. Similar findings were also reported by 
Mitsuanga et al. in a xenograft mouse model using a 
single PIT treatment [7]. A later publication by the same 
group demonstrated improved control of local tumor 
recurrence with repeated administration of PIT in treated 
mice with whole tumors [11], suggesting that multiple 
treatments would likely promote eradication of residual 
disease in an incomplete resection model. Furthermore, 
the pieces of tumor reimplanted in this model, even in 
the 90% resection group, were macroscopically visible, 
and therefore much larger than microscopic amounts left 
in a true post- resection wound bed. Thus, it is reasonable 
to expect even greater control of locoregional tumor recur-
rence in a more realistic clinical setting.
The majority of studies describing the efficacy of PIT 
have been performed using in vitro and in vivo xenograft 
studies [7–11]. The major disadvantage to this, of course, 
is the lack of clinical translatability of these highly pre-
clinical models [14]. The tumor and its surroundings may 
have a significant influence on the therapeutic potential 
of PIT, especially given that the mechanism of phototoxic 
cell death induced by Pan- IR700 remains poorly under-
stood [7]. Therefore, for what we believe to be the first 
time, PIT- induced cytotoxicity using Pan- IR700 was 
assessed in patient- derived tumor specimens. A significant 
reduction in cell viability was observed in the presence 
of the photosensitizer and 100 or 150 J cm−1 of PIT, 
further validating the feasibility and potential value of 
this technology to be advanced to clinical studies.
After human SCCHN tissue samples were incubated 
with Pan- IR700, fluorescence histology demonstrated a 
strong correlation between fluorescence, EGFR expression, 
and cancer, and did so in a dose- dependent manner. This 
study demonstrates highly specific binding of Pan- IR700, 
which is consistent with testing of target- specific binding 
of this agent using various assays by our laboratory and 
others using Pan- IR700 [7–9].
In conclusion, our results indicate that PIT using 
Pan- IR700 demonstrates great potential as an adjuvant 
treatment modality to intraoperatively and postoperatively 
eliminate residual microscopic disease following incomplete 
resections, thereby aiding the surgeon in obtaining a more 
radical resection while preserving as much functionality 
as possible with minimal collateral damage to normal 
tissues. Furthermore, the efficacy of this technology on 
fresh human cancer tissue adds to the growing body of 
evidence supporting the clinical translation of this 
technology.
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